Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • NovaBay Pharmaceuticals' Net Income towards Common Stockholders rose 4167.79% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.5 million, marking a year-over-year increase of 8512.03%. This contributed to the annual value of -$8.6 million for FY2024, which is 4926.62% up from last year.
  • As of Q3 2025, NovaBay Pharmaceuticals' Net Income towards Common Stockholders stood at -$1.3 million, which was up 4167.79% from -$1.2 million recorded in Q4 2024.
  • NovaBay Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at -$111000.0 during Q1 2022, with a 5-year trough of -$9.4 million in Q4 2023.
  • Over the past 5 years, NovaBay Pharmaceuticals' median Net Income towards Common Stockholders value was -$1.9 million (recorded in 2021), while the average stood at -$2.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 4137701.92% in 2021, then surged by 9268.77% in 2022.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Net Income towards Common Stockholders stood at -$893000.0 in 2021, then crashed by 818.92% to -$8.2 million in 2022, then decreased by 15.03% to -$9.4 million in 2023, then skyrocketed by 87.16% to -$1.2 million in 2024, then dropped by 6.68% to -$1.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$1.3 million in Q3 2025, compared to -$1.2 million in Q4 2024 and -$2.2 million in Q3 2024.